Pamuk Gülsüm Emel, Turgut Burhan, Demir Muzaffer, Tezcan Fatma, Vural Ozden
Division of Hematology, Trakya University Medical Faculty, Edirne, Turkey.
Am J Hematol. 2006 Aug;81(8):631-3. doi: 10.1002/ajh.20671.
The most frequent autoimmune complication in chronic lymphocytic leukemia (CLL) is autoimmune hemolytic anemia (AIHA). There are various treatment modalities; however, there is not much experience with the use of the chimeric anti-CD20 monoclonal antibody rituximab in the autoimmune complications of CLL. Here, we present our patient with CLL and AIHA whose AIHA was unresponsive to various treatment modalities. The administration of 375 mg/m(2)/day rituximab weekly for four cycles halted hemolysis and resulted in resolution of the patient's anemia. One year after therapy, the patient is well with a normal blood count. Rituximab might be preferred over other treatment modalities in the autoimmune complications of CLL because it is effective and has fewer side effects than other therapies.
慢性淋巴细胞白血病（CLL）最常见的自身免疫并发症是自身免疫性溶血性贫血（AIHA）。治疗方式多种多样；然而，在CLL的自身免疫并发症中使用嵌合抗CD20单克隆抗体利妥昔单抗的经验并不多。在此，我们报告一例患有CLL和AIHA的患者，其AIHA对多种治疗方式均无反应。每周一次给予375 mg/m²的利妥昔单抗，共四个周期，停止了溶血，并使患者的贫血得到缓解。治疗一年后，患者情况良好，血常规正常。在CLL的自身免疫并发症中，利妥昔单抗可能比其他治疗方式更受青睐，因为它有效且副作用比其他疗法更少。
